{"name":"Tennessee Retina","slug":"tennessee-retina","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Intravitreal Aflibercept Injection 2mg","genericName":"Intravitreal Aflibercept Injection 2mg","slug":"intravitreal-aflibercept-injection-2mg","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Intravitreal Aflibercept Injection 2mg","genericName":"Intravitreal Aflibercept Injection 2mg","slug":"intravitreal-aflibercept-injection-2mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPZmpTS2c5V29Vcm1DWTF4NHd2c2ctLWhJQl9jUGw2UmkyUUR4Rm9zaVZHbjhxa3NJaTZyRFJnUjhfS3JRUlYzWlZXcFRpNU5vQktiXzg4LVdqQ3oyVmVBN0otSVRFU0V3V1REcmc5MllpeTJhVzRoSm1QTlhXY1FBVkFSNFNGczFWT2w1M0dKRkFURnQ5ZnpYeA?oc=5","date":"2025-09-05","type":"pipeline","source":"Voice of Healthcare","summary":"Roche Secures EU CE Mark for Contivue® with Susvimo® in nAMD - Voice of Healthcare","headline":"Roche Secures EU CE Mark for Contivue® with Susvimo® in nAMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPdU5LUU1tS0VuamVxTnhOUGlpeTZWSWdqaUhIS2gxSk54bDdybXJFOW1aR1Jma2F1VW50UXdvTnBsck1lNWJSWTMyLVVZOGUwNHVvY2FtMXNid0dGR1hUandHMUx4d0lvcV82TkxUS0hnY240bk5TRWo4RmVqdDF1RmRONHhMWjIxLWlJellxYlhDcm0xUjdGQUliMGlpYkRXeDQ4anluOUl2MW1OSVRYTGdZNURibmU4bTZKTzFR0gHEAUFVX3lxTE9pMXV3YWZsMVlEYWxNejRGbV9nbmdLaXVvcmdjdTFyYnl4aDFCbXhFV3JMa0JJVTdZUDYwTV9ucmFtMVlZaG01YUZhNGlXSGpQNlQ2dFJFOHZEZ3NxSE81SGE0X3JNRDBNaGZoRnRpSHlUaG1ZSUdOTUtNYVRPYmRZZzU5YVp1bVJVVjNwZVl5eFpRZkZ2RDdYR191Nnhkdi1jQ21yMVFUMEkyTVB5czZDdS1HMXRBeDB6RDQ0SjZ0QjNNYWo?oc=5","date":"2024-03-05","type":"pipeline","source":"The Hindu","summary":"Roche pharma launches Vabysmo for retinal conditions - The Hindu","headline":"Roche pharma launches Vabysmo for retinal conditions","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}